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The objective of this work was to describe requirements for inclusion of soluble biomarkers in osteo-
arthritis (OA) clinical trials and progress toward OA-related biomarker qualiﬁcation.
The Guidelines for Biomarkers Working Group, representing experts in the ﬁeld of OA biomarker
research from both academia and industry, convened to discuss issues related to soluble biomarkers and
to make recommendations for their use in OA clinical trials based on current knowledge and anticipated
beneﬁts.
This document summarizes current guidance on use of biomarkers in OA clinical trials and their utility
at ﬁve stages, including preclinical development and phase I to phase IV trials.
As demonstrated by this summary, biomarkers can provide value at all stages of therapeutics devel-
opment. When resources permit, we recommend collection of biospecimens in all OA clinical trials for a
wide variety of reasons but in particular, to determine whether biomarkers are useful in identifying those
individuals most likely to receive clinically important beneﬁts from an intervention; and to determine
whether biomarkers are useful for identifying individuals at earlier stages of OA in order to institute
treatment at a time more amenable to disease modiﬁcation.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
In 1996, a task force of the Osteoarthritis Research Society In-
ternational (OARSI) published recommendations for the conduct
of clinical trials in osteoarthritis (OA)1. At that time, theyV.B. Kraus, Box 104775, Duke
A. Tel: 1-919-681-6652; Fax:
ternational. Published by Elsevier Lpresciently stated that, “as part of the advancement of science, it is
expected that OA protocols will contain both validated measures
and investigational outcome measures still requiring validation”.
Since then the ﬁeld of OA-related biomarkers has undergone
considerable advancement and there are many biomarkers
currently in various states of “validation”, or to be more precise,
qualiﬁcation2,3. Qualiﬁcation is the evidentiary process of linking a
biomarker with biological processes and clinical end points4e6.
More recently, qualiﬁcation has been described as a conclusion
that within the stated context of use, the drug development tool
(DDT) (i.e., biomarker) can be relied on to have a speciﬁctd. All rights reserved.
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tory review7. Thus, the Steering Committee of the OARSI Task Force
on Recommendations for Conducting Clinical Trials in Osteoar-
thritis deemed it appropriate and necessary to include a descrip-
tion of the process and issues related to inclusion of biomarkers in
OA clinical trials.
A biomarker is deﬁned as a characteristic that is objectively
measured and evaluated as an indicator of normal biologic pro-
cesses, pathogenic processes, or pharmacologic responses to a
therapeutic intervention6. Among other things, biomarkers in the
OA ﬁeld can be used in drug and other therapeutics development,
treatment monitoring and the future basis of personalized
evidence-based action plans, disease monitoring and prognosis.
The long-term goal is to contribute to strategies that improve the
lives of people with OA or who are at risk of OA. Biomarkers include
not only soluble analytes measured in biospecimens such as blood
and urine, but anatomic biomarkers such as ﬁndings detected by
radiography and magnetic resonance imaging (MRI), physiological
measurements such as gait analyses and even histological mea-
surements produced as a result of a joint tissue biopsy such as a
synovial biopsy. The goal of this report is to discuss issues related
speciﬁcally to soluble biomarkers and tomake recommendations for
their use in OA clinical trials based on current knowledge and
anticipated beneﬁts.
Biomarker development generally stems from an understanding
of the pathophysiology of a disease4. It is little wonder then that
biomarker development in OA is burgeoning as we gain a more
clear understanding of the disease, its stages, and various pheno-
types. Many of the existing OA-related biomarker assays have
grown directly out of an understanding of joint tissue meta-
bolism8,9 and reﬂect catabolism or anabolism of joint tissues. To the
extent that many of the products of joint tissue metabolism can
stimulate an innate immune response (for instance ﬁbronectin and
hyaluronan fragments)10e13, and be detected in biospecimens3,14,15,
there is a potential to have some OA-related biomarkers that are
directly involved in the pathophysiology of an OA disease outcome.
This is an enviable scenario that has rarely been achieved in other
disease areas but represents the holy grail of biomarker develop-
ment. Probably the paradigm of such a biomarker is cholesterol;
high serum total and LDL-cholesterol are regarded as reﬂecting the
pathophysiological events leading to atherosclerotic cardiovascular
disease4. Work is currently underway in the OARSI/Foundation for
NIH OA Biomarkers Consortium study3 to qualify a panel of OA-
related soluble markers (serum and urine) as predictors of a clini-
cally relevant outcome consisting of the combination of knee OA
radiographic worsening and pain worsening.
A great deal of guidance exists, and is growing rapidly, regarding
the topic of biomarker development for use in clinical trials
(described below). Reporting in 201016, and in 2012 applied to
omics technologies17, the Institute of Medicine (IOM) recom-
mended a framework for the evaluation of biomarkers to lead to
their clinical application. They recommended that the Food and
Drug Administration (FDA) use the same degree of scientiﬁc rigor
for evaluating biomarker use across all regulatory areas (drugs,
medical devices, biologics, foods and dietary supplements) and for
this purpose proposed a three-part framework for biomarker
evaluation:
(1) Analytical validationdevaluation of the analytical perfor-
mance of the test to ensure the biomarker test is reliable,
reproducible, and adequately sensitive and speciﬁc;
(2) Qualiﬁcationdto ensure the biomarker is associatedwith the
clinical outcome of concern;
(3) Utilization analysisdto determine that the biomarker is
appropriate for the proposed use.They further recommended that the initial evaluation of
analytical validation and qualiﬁcation should be conducted sepa-
rately from a particular context of use. They concluded that,
“Modern medicine depends on biomarkers”18.
We will cover each of these topics, ﬁrst focusing on the issues
and guidance related to the process of qualiﬁcation of biomarkers
for different contexts of use, second on their utilization pertaining
to each phase of OA clinical trials, and third we discuss aspects of
analytical validation of OA-related biomarkers. Although we refer
primarily to the rich guidance available from the FDA and highlight,
when available corresponding information provided by the Euro-
pean Medicines Agency (EMA), we anticipate that this information
will be applicable and of use in all countries. We will summarize
statistical considerations that are pertinent to biomarkers in OA
trials. Finally, we propose a research agenda that emerges from this
update in order to assist in advancing the ﬁeld. We note that the
research agenda from such endeavors can be very valuable as
evinced by the previous OARSI/FDA white paper on the subject19
that led to the current OARSI/Foundation for NIH OA Biomarkers
Consortium study comparing a large panel of biochemical and
imaging biomarkers for their predictive capabilities3.
The working group for this review included all individuals with
extensive OA-related biomarkers expertise; the group consisted of
two rheumatology physician scientists (VBK, FB), one orthopaedic
surgeon physician scientist (SL), one clinical epidemiologist (ME),
one basic scientist with expertise in physical therapy and rehabil-
itation (YH), one biostatistician with expertise in outcomes
research (EL), one basic scientist with expertise in musculoskeletal
tissue analysis (PO), and one research industry scientist with
expertise in translational medicine and regulatory affairs (SP).
Guidance on use of biomarkers in OA clinical trials
Approach to clinical trial use of OA-related biomarkers
In 1992, the FDA posted rules and regulations in the Federal
Register20 regarding approval of drugs for “serious or life-
threatening illnesses” based on “evidence from adequate and
well-controlled studies of the drug's effect on a surrogate endpoint
that reasonably suggests clinical beneﬁt or on evidence of the
drug's effect on a clinical endpoint other than survival or irre-
versible morbidity”. This guidance was updated in 2014 and
deﬁned a serious disease or condition as follows: “a disease or
condition associated with morbidity that has substantial impact on
day-to-day functioning. Short-lived and self-limitingmorbidity will
usually not be sufﬁcient, but the morbidity need not be irreversible
if it is persistent or recurrent. Whether a disease or condition is
serious is a matter of clinical judgment, based on its impact on such
factors as survival, day-to-day functioning, or the likelihood that
the disease, if left untreated, will progress from a less severe con-
dition to a more serious one”21. Importantly, this deﬁnition en-
compasses many aspects of the OA experience. This guidance
describes a mechanism for expedited approval of drugs that may
provide meaningful therapeutic beneﬁt compared to existing
treatment. After approval under these regulations, continued study
of the drugs' clinical beneﬁts and restrictions on use might be
mandated, pending completion of studies to establish and deﬁne
the degree of clinical beneﬁts to study participants. Thus, this
mechanism could be considered a conditional approval mecha-
nism. This mechanism of approval is important for our consider-
ation as soluble biomarkers might play a role in the conditional
approval process and further, that this mechanism might be the
stepping stone to a new drug development pathway in OA. This
pathway would allow approval of “a drug that treats a serious
condition AND generally provides a meaningful advantage over
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endpoint that is reasonably likely to predict clinical beneﬁt or on a
clinical endpoint that can be measured earlier than irreversible
morbidity or mortality (IMM) that is reasonably likely to predict an
effect on IMM or other clinical beneﬁt (i.e., an intermediate clinical
endpoint)”21. To support this mechanism of approval, it will be
important to further our understanding and recognition of the
serious nature of OA, promote development and widespread use of
uniform deﬁnitions of OA, and gain a greater appreciation of the
burden of OA at an individual and societal level.
A recent report underscores the major global disability burden
of OA, including low back pain22e24. However, the systematic
analysis for the Global Burden of Disease Study 2010 split OA-
related conditions into separate categories such as low back pain,
neck pain and OA (type not speciﬁed). Research is needed to ac-
count for all forms of OA so as to gain a holistic assessment of its
true burden; for instance, it will be important to understand the
proportion of neck and low back pain that is attributable to OA.
Currently, our inability to deﬁnitively identify and quantify OA in all
its forms, hampers our ability to form a holistic assessment of its
true global impact. This problem in the ﬁeld is potentially accessible
by systemic biomarkers. Murray et al. acknowledge that these
musculoskeletal conditions are extremely common, that the
burden is likely to grow, the symptoms are underestimated and
research is urgently needed to develop effective and affordable
strategies for dealing with these disorders22. These conclusions
would seem to be consonant with the seriousness criterion needed
for pursuing a conditional drug approval on the basis of surrogates.
Types of biomarkers
The BIPEDS classiﬁcation system (standing for Burden of dis-
ease, Investigational, Prognostic, Efﬁcacy of intervention, Diag-
nostic and Safety) describes one broad level of potential
classiﬁcation and contexts for qualiﬁcation19,25. The correspon-
dence of these terms with those of the FDA is shown in Table I. Note
that the BIPEDS general category of prognostic biomarkers includes
both prognostic and predictive markers per FDA deﬁnitions and the
efﬁcacy of intervention category includes pharmacodynamic (or
activity) biomarkers per the FDA nomenclature in guidance docu-
ments. The three biomarker categories of prognostic, efﬁcacy of
intervention and safety are the highest development priorities for
OA clinical trials; this is due to the fact that at present, the diagnosis
of OA for meeting enrollment criteria is based on a combination of
symptoms and established anatomic abnormalities identiﬁed by an
imaging technique such as MRI or radiographic abnormalities. It is
conceivable that in the future, OA trials will be conducted onTable I
Summary of “BIPEDS” biomarker classiﬁcation for OA and comparison with FDA
terms
Category
B Burden of Disease Biomarker associated with extent of severity of OA
I Investigative Biomarker not yet meeting criteria for another category
P Prognostic Predicts incidence or progression of disease
(FDA prognostic biomarker) or likelihood of response
to a treatment intervention (FDA predictive biomarker)
E Efﬁcacy of
Intervention
Indicative of treatment efﬁcacy (FDA pharmacodynamic
or activity biomarker) and for which the magnitude
of the change is considered pertinent to the response.
Surrogates form a subset category of biomarkers
intended to substitute for a clinical efﬁcacy endpoint
D Diagnostic Differentiates diseased from non-diseased
S Safety Identify adverse effects and provide means of safety
surveillance
Based on Bauer et al.25 and7.individuals at earlier stages of disease development that might
require diagnostic biomarkers to identify the appropriate patient
population and verify a diagnosis of early OA that would not yet be
possible by an existing imaging technique. A recent exciting event
in the ﬁeld has been the discovery of differences, at a molecular
level, between the cartilages at different sites in the body26.
Coupled with the recent demonstration that cartilages differ in
their anabolic responses by joint site and disease state27, joint type
speciﬁc biomarkers would appear to be in reach for OA.
Contexts of use and importance of patient phenotyping
Patient phenotyping is critical to the success of biomarker
qualiﬁcation. OA is a tremendously heterogeneous group of
different phenotypes of disease at different joint locations and
different combinations thereof. It is possible that biomarkers will
perform very differently in these different phenotypes; for
instance, biomarkers for early onset post-traumatic knee OA might
be very different from valid biomarkers for erosive hand OA.
The subject sample needs not only to be carefully detailed with
respect to conventional demographic characteristics, i.e., age, sex,
body mass index, comorbidities, etc., but also the targeted OA
phenotype, joint location(s) and its disease stage depending on
study purpose such as diagnostic, efﬁcacy monitoring, or safety
monitoring. As demonstrated by the experience with prostate
cancer biomarkers, there is a need for a standardized procedure to
validate new biomarkers to achieve comparability28. In addition to
comprehensive phenotyping, very precise conditions are also
needed for sample collection, handling and storage, as summarized
below in the section on analytical validation.
One current major challenge is our lack of universal criteria to
phenotype and characterize different stages of early OA. To facili-
tate interpretation and comparability of biomarker studies across
trials, study participants need to be described in detail with respect
to symptoms, structure, function, and other known risk factors and
medications. Thewhite papers on clinical trial recommendations of
the other working groups of this task force are providing infor-
mation to ultimately create a standardized environment inwhich to
qualify OA biomarkers.
Here we provide only a few examples of OA phenotypes from
the overall spectrum of phenotypes that may be suitable for
biomarker trials:
(a) Previously uninjured men and women, aged 25 to 35 with
acute anterior cruciate ligament injury (<4 weeks old) with
or without primary arthroscopic ligament reconstruction or
meniscectomy. The status of other joints is normal.
(b) Postmenopausal women with symptomatic and disabling
(>6 months) bilateral multi-joint erosive hand OA as detec-
ted by MRI; other joints asymptomatic.
(c) Individuals aged 40 or older with new onset unilateral knee
pain (<6 months) without knee trauma, but with normal
knee radiograph. Knee MRI shows meniscal pathology
(extrusion/degenerative tear), subchondral bone marrow
lesion, effusion and/or minor tibiofemoral cartilage defect(s).
(d) Symptomatic and radiographic knee OA.
(e) Symptomatic and radiographic hip OA.
Structure-based outcomes, for instance fromMRI, ultrasound or
scintigraphy to name a few, need to be carefully deﬁned, preferably
using validated scoring systems29. The current fast development of
compositional MRI, which has the potential for earlier detection of
progression, creates a promising future in which to develop out-
comes and endpoints that may allow for much shorter follow up
times than the classic loss of joint space on conventional
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typing is critical to the success of biomarker qualiﬁcation. It is
generally believed that OA trials have failed to succeed to date due
to the insensitivity of the clinical outcome measure, namely
radiographic joint space narrowing, mandated by regulatory
agencies. Examples from other ﬁelds illustrate the impact of the
clinical efﬁcacy measure. For instance, the validity of blood pres-
sure measures as surrogates depended quite strongly on the deﬁ-
nition of the clinical efﬁcacy measures because blood pressure
measures were very predictive of effects on stroke, less predictive
of effects onmyocardial infarction, cardiovascular death and overall
mortality, and poorly predictive of effects on heart failure (sum-
marized by Fleming et al.30). Thus, when using a biomarker as a
substitute for a clinically meaningful endpoint, one must ﬁrst be
clear about the clinically meaningful endpoint for which the
biomarker is a proposed surrogate30.
The FDA guidance states (as described in Table II) that their
qualiﬁcation process is intended to provide some degree of
generalizability for use of the toolsdsuch as their use across mul-
tiple clinical disorders, drugs, or drug classes. We would therefore
anticipate that drug development programs could utilize bio-
markers qualiﬁed for particular contexts of use. For instance, a
biomarker qualiﬁed for OA progression, and modiﬁed by in-
terventions that block progression, might be used as a tool for
development of a chondroprotective agent.
Guidance on biomarkers as DDTs
Several converging observations have led to the increasing
emphasis on biomarkers in drug development and a process for
their qualiﬁcation. First, it is clear that not all individuals respond
favorably to speciﬁc therapeutic interventions including drugs. The
use of biomarkers can help identify individuals that are more likely
to respond favorably to a given therapy. Increasingly, biomarkers
are applied to the stratiﬁcation of different patient groups in terms
of clinical response, so as to develop personalized, preventive or
therapeutic strategies31. The FDA has recognized the importance of
biomarkers in personalized medicine32. Starting in 1998 with the
approval of trastuzumab (Herceptin, Genentech) for the treatment
of HER2-positive breast cancers, the FDA has approved more than
100 drugs that contain speciﬁc information about biomarkers in the
labeling33.
A second impetus to biomarker guidance originated with the
Omnibus Appropriations Act of 2009 that included funds for an IOM.Table II
Rationale for new approach to development of DDTs
Points Description
1 Once a DDT is qualiﬁed for a speciﬁc context of use, industry can
use the DDT for the qualiﬁed purpose during drug development,
and CDER reviewers can be conﬁdent in applying the DDT for the
qualiﬁed use without the need to reconﬁrm the suitability of the DDT.
2 Because of the substantial work needed to achieve qualiﬁcation,
CDER encourages the formation of collaborative groups to undertake
these tool-development programs to increase the efﬁciency of joint
efforts and to lessen the resource burden upon any individual person
or company working to gain qualiﬁcation for a tool.
3 DDT acceptance in the drug development and regulation process has
previously been on a sponsor-by-sponsor, drug-by-drug basis.
4 If a DDT is qualiﬁed under this guidance, the qualiﬁed DDT will be
made publicly available for use by sponsors of any drug or biologic
investigational new drug (IND) or new drug application (NDA) or
biologics license application (BLA).
5 The new guidance is intended to provide some degree of
generalizability for use of the tool such as use across multiple
clinical disorders, multiple drugs, or drug classes.
Based on two FDA guidance documents7,34.Compelled by applications to the Center for Food Safety and Applied
Nutrition of the FDA for approval of health claims for foods, most of
which reﬂected claims of effects on a biomarkerdthe IOM was
tasked to recommend a framework for the evaluation of biomarkers
and to make ancillary recommendations for their application18.
The FDA recognized, in the Critical Path Initiative launched in
2004, that the advancement in knowledge about the biology of
diseases has not resulted in the commensurate increase in effective
new drugs (http://www.fda.gov/scienceresearch/specialtopics/
criticalpathinitiative/default.htm). To improve the drug develop-
ment process, the FDA recognized that the application of those
scientiﬁc advances to drug development should make this process
more efﬁcient. Such tools should ultimately produce products with
greater safety and efﬁcacy and most importantly, reduce the attri-
tion rate, i.e., drugs not reaching a marketing authorization during
advanced clinical development. This engendered a third type of
guidance, a rationale for a new approach to development of
DDTs that was provided by the FDA in 2010 (summarized in
Table II)34. In 2014 the FDA released a second guidance further
describing the qualiﬁcation process for DDTs7. The guidance pro-
vides a framework for interaction between the Center for Drug
Evaluation and Research (CDER) and the sponsor (pharmaceutical
ﬁrms, academic institutions, consortia, etc.) proposing the DDT for
qualiﬁcation.
A DDT could be a biomarker, a clinical outcome assessment, or
an animal model. Biomarker qualiﬁcation has been recognized by
the FDA as a signiﬁcant area of interest, either as a single biomarker
or as a composite biomarker, the latter consisting of several indi-
vidual biomarkers combined in a stated algorithm to obtain an
easily interpretable readout. The guidance also contains an indi-
cation on howa sponsor should formulate the so-called “Context Of
Use” (COU). These include a “use statement” (the name of the
biomarker and the speciﬁc purpose for use in drug development)
and a description of conditions for the biomarker to be used in the
qualiﬁed setting that are termed “condition for qualiﬁed use” (the
conditions for the use of the biomarker in the qualiﬁed setting). In
summary, the process of biomarker qualiﬁcation is made up of
several steps:
(1) Identiﬁcation of the biomarker as soluble/‘wet’ (biochemical
analyte, genomic, etc.) or non-soluble/‘dry’ (imaging physical
examination ﬁnding, scales, etc.);
(2) Aspect of the biomarker measured and indication for correct
interpretation (i.e., single time point vs area under the curve
(AUC) of a receiver operator characteristic curve, post-
treatment vs pre-treatment);
(3) Animal species or subjects studied (strain, age, sex, ethnicity,
disease phenotype, etc.);
(4) Purpose in drug development (patient phenotyping, assess-
ment of efﬁcacy and/or safety, etc.);
(5) Drug development circumstances for applying the biomarker
(nonclinical vs clinical);
(6) Interpretation and decision/action based on the biomarker
(threshold that indicates beneﬁcial physiological response,
threshold that indicates organ toxicity, individuals that are
more likely to respond to treatment, individuals that are
more likely to experience adverse effects).
Finally, the steps described above should be integrated in a
decision tree that clariﬁes, in the context of use, the actions that
would be taken based on the biomarker results. The steps involved
in qualiﬁcation are listed in Fig. 1 and based on the most recent FDA
guidance7. With the advent of a clear pathway to biomarker qual-
iﬁcation, work is ongoing to establish DDTs for OA-related trials and
ultimately clinical use.
Fig. 1. The qualiﬁcation process for DDTs. This schematic is based on a 2014 FDA guidance document related to the biomarker qualiﬁcation process7. Since 2008, four submitters
have been granted qualiﬁed biomarker status from the FDA for biomarkers related to nephrotoxicity, cardiotoxicity and lung infection with aspergillosis. Draft guidance and
supporting information on these qualiﬁed biomarkers can be found listed at the FDA website on the Biomarker Qualiﬁcation Program (http://www.fda.gov/Drugs/
DevelopmentApprovalProcess/DrugDevelopmentToolsQualiﬁcationProgram/ucm284076.htm). CDER ¼ the Center for Drug Evaluation and Research; DDT ¼ Drug Development
Tool; QRT ¼ Qualiﬁcation Review Team; FDA ¼ United States Food and Drug Administration.
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offers scientiﬁc advice related to novel methodologies intended for
use as tools in clinical drug development (http://www.ema.europa.
eu/docs/en_GB/document_library/Regulatory_and_procedural_
guideline/2009/10/WC500004201.pdf). This guidance was
approved by the Committee for Medicinal Products for Human Use
(CHMP) in 2009 and has been revised twice. It now includes dates
and deadlines for submission of letters of intent for qualiﬁcation of
novel methodologies and addresses the following procedures,
which are quite similar to the process adopted currently also by the
FDA (from http://www.gmp-compliance.org/enews_04089_New-
EMA-Guidance-Qualiﬁcation-of-novel-Methodologies-for-Drug-
Development.html):
 Intention to submit a request
 Appointment of the Coordinator and the Qualiﬁcation team on
behalf of the Committee for Medicinal Products for Human Use
CHMP)
 Preparatory meeting
 Evaluation of data and discussion with the applicants
 Scientiﬁc Advice Working Party (SAWP) review
 CHMP adoption of Qualiﬁcation Advice and discussion of Qual-
iﬁcation Opinion
 Public consultation (for Qualiﬁcation Opinion only)
 Adoption of the ﬁnal CHMP Qualiﬁcation Opinion
An overview of the comments received on the EMA draft
guidance document on qualiﬁcation of biomarkers can be found at
the following url: www.ema.europa.eu/docs/en_GB/document_
library/Regulatory_and_procedural_guideline/2009/10/
WC500004202.pdf.Utilization of biomarkers as DDTs for OA clinical trials
Biomarkers could provide value and be involved in OA-related
drug development at preclinical stages and throughout clinical
development in phase I to IV trials. Below we summarize consid-
erations for each of these phases of drug development and trial
work.
 Preclinical Work
 Assess drug safety
 Assist with selection of animal models and lead compounds
 Assess drug mechanism of action
The majority of biomarker use in drug development is in the
early phases involving the internal decision making process related
to determining which drugs to progress35. At the preclinical level,
three major applications of biomarkers are their use in toxicology
studies36, their use to help select appropriate animal models and
lead compounds4,37 and their use to determine or reﬁne the
mechanism of action of a compound4. In toxicology studies, the
goal is to use safety biomarkers in assisting in the selection of drug
candidates that are more likely to be tolerated in humans, thereby
reducing cost and time required for preclinical safety evaluation36.
Potential clinical biomarkers of drug efﬁcacy are often identiﬁed
through pre-clinical studies or basic research37. Biomarkers veriﬁed
for use in clinical trials can conﬁrm a drug's pharmacological or
biological mechanism of action, guide protocol design, aid patient
and dose selection, and help to minimize safety risks37. Floyd and
McShane separate biomarkers into three tiered sets that predict
compound efﬁcacy with increasing conﬁdence: level 1 to conﬁrm
pharmacological mechanism of action; level 2 to demonstrate
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outcome37. All three of these levels represent different types of
efﬁcacy of intervention biomarkers per the BIPEDS classiﬁcation.
They can be employed both in preclinical studies and clinical trials
in humans. As they note for the oncology ﬁeld, “Most companies
now have requirements for the incorporation of biomarker strate-
gies into clinical development plans, and success of this approach
to drug development will require the consistent and timely de-
livery of new biomarkers having a level of robustness and valida-
tion that matches or exceeds the signiﬁcance of the decisions they
will be designed to support”37.
 Phase I Trials
 Assess mode of action
 Assist with dose ﬁnding and selection
 Assess safety via surveillance of effects on joint metabolism
Phase I studies during drug development are the ﬁrst studies
involving humans and provide answers to important questions
about a potential new drug38. The main objective of Phase I studies
is to assess the safety of the product after single and repeated doses.
Secondary objectives are to evaluate the pharmacokinetics (what
the body does to the drug) and, if possible, the pharmacodynamics
(what the drug does to the body). The latter two issues are relevant
as they provide the ﬁrst preliminary indication in humans of
whether a new molecule has the potential to be effective based on
ease of use (dose and frequency of dosing) and potency (based on
preclinical in vitro and in vivo studies). The pharmacokinetic (PK)
proﬁle determined in Phase I studies provides an understanding of
whether the plasma concentrations are adequate to engage the
pharmacological target with at most two or three administrations
per day of the drug while simultaneously maintaining a suitable
safety margin compared to the exposure observed in toxicological
studies. Therefore, in order to be a pharmacodynamic (PD)
biomarker in Phase I, the biomarker must be linked to the mech-
anism of action of the new chemical entity, demonstrate whether
the administered compound reaches the target receptor and does
so in sufﬁciently high concentrations, and that this occurs at sys-
temic exposure unlikely to generate adverse events based on the
product toxicological proﬁle. The biomarker is subsequently used in
phase I studies to build a dose response curve by linking the plasma
concentration observed at different doses with the concentrations/
response curves obtained in vitro on the target receptor39,40. When
the above-mentioned link is made, this is referred to as
Mechanism-based PK-PD modeling.
These processes differ from simple PK-PD models in that they
include the quantitative evaluation of additional steps from drug
administration to effect. This includes target site distribution,
binding and activation, pharmacodynamic interactions, trans-
duction and homeostatic feedback mechanisms. Important progress
has been made in the ﬁeld of mechanism-based PK-PD modeling
through the incorporation of concepts from receptor theory39,40.
Receptor theory is the application of receptor models to explain drug
behavior. For instance, the inclusion of receptor theory concepts for
characterization of target binding and target activation processes
results in improved prediction of the pharmacological active dose
and/or doses. Speciﬁcally, receptor theory constitutes a scientiﬁc
basis for the prediction of in vivo drug concentrationeeffect re-
lationships. To this end, biomarkers need to be used early during the
drug development process and information needs to be gathered
and continuously updated to ensure the reliability of the results.
Phase I studies are usually conducted in healthy volunteers and
sometimes in individuals with the disease. Regardless of the pop-
ulation enrolled, since OA is a chronic disease, it is obvious that the
availability of biomarkers in Phase I for OA drugs will accelerate theunderstanding of the potential efﬁcacy of a new chemical entity as
modulation of the biomarker, linked to the drug mechanism of
action, would be expected to occur within a signiﬁcantly shorter
period than that needed to reach the clinical endpoint41. OA drug
development is one of the therapeutic indications that could
potentially stand to beneﬁt most from the use of biomarkers during
early clinical development. An early indication of efﬁcacy would
reduce the risk of failure during long and expensive Phase III clinical
trials and therefore, make the drug development process more
efﬁcient, shortening time to market, and allowing more accurate
decisions regarding investments.
A biomarker in Phase I can be used not only to assess the ex-
pected therapeutic effects but equally important, to monitor for
unwanted side effects. Ideally, drug development should beneﬁt
from biomarkers capable of monitoring the efﬁcacy (linked to the
mechanism of action of the drug) and the safety (allowing for
instance, the monitoring of the function of an organ known to be a
target for toxicity from toxicological investigations) of an experi-
mental drug. These would allow an understanding of whether a
favorable therapeutic index can be expected in treated individuals.
 Phase II Trials
 Serve as an early objective indicator of drug effect
 Assist in identifying the minimal effective dose and dose
response proﬁle
 Facilitate Multiple Comparison Procedure Modeling (MCP-
Mod)duse of modeling and simulation during Phase II to aid
dose selection for Phase III clinical trials in OA
Typically, biomarkers play a less-exploratory role but are rather
used as key decision points in phase IIb and phase III stage devel-
opment35. Phase II studies are the most critical trials in drug
development as they generate the ﬁrst proof of concept regarding
potential clinical efﬁcacy. Careful study design and conduct is of
paramount importance to reduce the risk of failure during later
Phase III trials. One of the most important aspects that must be
taken into consideration is the construction of an accurate dose
response relationship for both safety and efﬁcacy to ensure themost
appropriate dose range and/or ranges are taken further and tested in
subsequent Phase III trials. Recent advances in the design of Phase II
studies include application of computer tools tomodel and simulate
clinical trials42. Modeling and simulation applied in Phase II are
based on the availability of a biomarker linked either to the mech-
anism of action of the drug, or to a potential unwanted effect, or
both. Modeling and simulation allow an appropriate dose selection
for Phase III studies to ensure optimal efﬁcacy and safety in real
clinical practice, thus moving from “efﬁcacy” (the drug is capable of
affecting the disease phenotype in a controlled trial) demonstrated
in Phase II and III to “effectiveness” (the drug is capable of producing
clinically relevant beneﬁts in the “real” practice of medicine). To
streamline the drug development process and reduce the risk of
failure, major pharmaceutical companies are developing modeling
and simulation tools alone or in conjunctionwith other companies.
One example is the Multiple Comparison Process-Modeling (MCP-
Mod) developed by Novartis43 that was also recently qualiﬁed by
requesting the EMA opinion on the topic44.
US and European Regulatory Agencies encourage pharmaceutical
companies to increase the use of modeling and simulation tools and
to this end have even created dedicated divisions specialized in the
relatively new science called pharmacometrics (http://www.fda.gov/
AboutFDA/CentersOfﬁces/OfﬁceofMedicalProductsandTobacco/CDER/
ucm167032.htm). Pharmacometrics is becoming a fundamental
part of drug development that quantiﬁes drug, disease and trial in-
formation to aid not only efﬁcient drug development, but also regu-
latory decisions45. Pharmacometrics adds the individual patient
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(pharmacokinetics) and response (pharmacodynamics) for both
desired and undesired effects. Disease models describe the relation-
ship between biomarkers and clinical outcomes, time course of dis-
ease andplacebo effects.Modelingwill thus facilitate thedeﬁnition of
the inclusion/exclusion criteria, study participant discontinuation
and adherence based not only on the safety and efﬁcacy of the drug,
but also on the interaction of these with the individual's character-
istics. This will ultimately allow identiﬁcation of populations that are
most likely to respond to treatment and/or those that aremore likely
to experience adverse events enabling enrichment study designs46.
Therefore, pharmacometrics aids in the selection of the right drug
dosing for all individuals thus greatly contributing to the determi-
nation of the value of a biomarker for both efﬁcacy and safety across
clinical trials for a given disease and/or for a drug class.
 Phase III Trials
 Increase study power and reduce sample size through
enrichment of an appropriate target population
 Shorten duration of trial
 Gain approval for different dose range not in original trial
based on clinical trial simulations with biomarkers
As described in a recent FDA guidance document47, enrichment
study designs are increasingly viewed as providing potential
beneﬁt to the drug development process. We can therefore envi-
sion biomarkers playing a role in identifying speciﬁc types of in-
dividuals (progressors, drug responders, etc.) for trial inclusion. In
our prior OARSI/FDA white paper on biomarkers19, we considered
biomarkers as likely serving as secondary rather than primary
endpoints. We can now conceive however, that with the formal
qualiﬁcation of a panel of OA-related biomarkers3, and the devel-
opment of a conditional approval mechanism for OA-related ther-
apeutics (as described above), that biomarkers could potentially
form a component of a primary endpoint. As described above, were
OA to be formally accepted as a serious disease for purposes of drug
approval by the FDA21, it might be possible for biomarkers that
predict clinical beneﬁt to be used for marketing approval of the
drug, with subsequent post-marketing conﬁrmatory trials to verify
the clinical beneﬁt.
 Phase IV Trials
 Deﬁne cost-effective means of safety surveillance during the
post-marketing phase of drug development
 Identify subgroups of responder or non-responder
individuals
 Monitor drug effectiveness and safety in real life conditions
The need for post-market surveillance becomes increasingly
important in this new era of personalized medicine as more and
more products are approved on the basis of very small clinical tri-
als32 e smaller pre-market exposure requires greater post-market
monitoring in the general population. In daily medical practice it
will be important to determine long-term risks and long-term
beneﬁts of drugs; to this end, biomarker surveillance could pro-
vide a minimally invasive and relatively cost-effective method to
monitor for both risks and beneﬁts of a drug on joint metabolism
and health.
Analytical validation
Guidance on bioanalytical validation
Validation refers to the measurement performance character-
istics of a biomarker4. Validation of a bioanalytical method isneeded to demonstrate that it is reliable and reproducible for the
intended quantitative measurement of the biomarker(s) in a given
biological matrix (e.g., blood, plasma, serum, or urine). When
changes are made to a previously validated method, additional
validation may be needed4. The FDA has provided comprehensive
guidance on analytical validation processes appropriate to bio-
markers; this document covers accuracy, precision, selectivity,
sensitivity, reproducibility and stability48.
 Strict standard operating procedures (SOPs) must be imple-
mented to control preanalytical variability and ensure a com-
plete system of quality control (QC) and assurance. SOPs should
cover all aspects of analysis, from the time the sample is
collected and reaches the laboratory until the results of the
analysis are reported. For details on methods of sample collec-
tion, type and timing of samples, see Appendices from prior
publications1,19, and Rai et al.49.
 Key reagents, such as reference standards, antibodies, tracers,
and matrices should be characterized appropriately and stored
under deﬁned conditions. When there are changes in any of
these, additional optimization or validation may be needed (e.g.,
checking cross-reactivities of an antibody).
 Matrix effects should be addressed such as ion suppression, ion
enhancement, or alterations of extraction efﬁciency. The FDA
guidelines advise measuring matrix effects by comparing spiked
minus unspiked donor samples in a number of donors (e.g., 10)
and looking at the appropriateness of the increase relative to the
original level of the spiked in sample.
 A calibration (standard) curve should be generated for each
biomarker in the sample, using standards that can contain more
than one analyte. The curve should be prepared in the same
biological matrix as the samples in the intended study by
spiking the matrix (e.g., serum, urine or synovial ﬂuid) with
known concentrations of the standards. Concentrations of
standards should be chosen on the basis of the concentration
range expected in the particular study. A calibration curve
should consist of a blank sample (matrix sample processed
without analyte or internal standard), a zero sample (matrix
sample processed without analyte but with internal standard),
and at least six non-zero samples (matrix samples processed
with analyte and internal standard) covering the expected
range, including the lower limit of quantiﬁcation (LLOQ).
 Most calibration curves of Ligand-Binding Assays (LBAs) are
inherently nonlinear and, in general, more concentration points
may be recommended to deﬁne the ﬁt over the standard curve
range than for chromatographic assays.
 The analytical method should be shown to be selective for the
biomarker, ensuring this selectivity at the LLOQ. Evidence
should be provided that the substance quantiﬁed is the intended
biomarker, thus blank samples should be tested for in-
terferences from substances similar to the biomarker tested;
cross-reactivity can also be evaluated for metabolites, concom-
itant medications and their signiﬁcant metabolites, or endoge-
nous compounds.
 Accuracy is assessed by measuring recovery of the spiked ana-
lyte tested in triplicate, in accordance with FDA guidance for
industry on bioanalytical method validation48. When possible,
LBAs (such as ELISA) should be compared with a validated
reference method (such as LCeMS) using incurred samples
(selected real study samples) and predetermined criteria to
assess the accuracy of the LBA method.
 Precision is measured using a minimum of ﬁve determinations
per concentration. The precision determined at each concentra-
tion level shouldnot exceed15%of the coefﬁcient of variation (CV)
except for the LLOQ, where it should not exceed 20% of the CV.
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surements using the assay, including QCs and possibly incurred
(selected real study samples) samples.
 The chemical stability of the biomarker in the matrix, under
speciﬁc conditions for given time intervals, should be assessed
in several ways. Pre-study stability evaluations should cover the
expected sample handling and storage conditions during the
conduct of the study, including, among others, conditions at the
clinical site and any secondary sites, conditions during shipment
and effects of freeze-thaw. Stability samples should be
compared to freshly made calibrators and/or freshly made QCs.
Testing is recommended to include a minimum of three con-
centrations in the range of expected study sample concentra-
tions. Themean value should bewithin 15% of the nominal value
except at LLOQ, where it should not deviate bymore than 20%48.
 The extent of recovery of a biomarker and its reference standard
from the sample should be consistent, precise, and reproducible.
 A full validation of the bioanalytical method is important for the
analysis of a new biomarker entity. In cases wheremodiﬁcations
are made on already validated methods, partial validations can
be performed. These can range from an intra-assay accuracy and
precision determination, to a nearly full validation.Bioanalytical platforms
Bioanalytical procedures for biomarker evaluation generally
belong to three different platforms: chromatographic methods,
such as liquid chromatography (LC) or gas chromatography (GC),
combined chromatography and mass spectrometry (MS) pro-
cedures, such as liquid chromatographyemass spectrometry
(LCeMS or LCeMSeMS), or ligand binding assays (LBAs, such as
ELISA or radioimmunoassays (RIAs). Most recently, approaches
combining LBAs with MS have been also developed50.
Among these different analytical platforms, ELISA technology
provides an unsurpassed high sensitivity combined with high
throughput, which makes this platform desirable for the ﬁnal
clinical assay. However, reliance on this technology has created a
bottleneck during biomarker veriﬁcation, since antibodies are often
poorly validated and the development of novel ELISAs is costly and
lengthy. This important limitation prevents ELISAs from being used
to interrogate large numbers of candidate biomarkers (peptides,
proteins or speciﬁc isoforms), which have been identiﬁed in MS-
based discovery strategies. The advent of proteomics has raised
the challenge of detecting and quantifying a larger number of
biomarkers from samples in a systematic and efﬁcient fashion. It is
clear that for complex diseases like OA, a multi-analyte biomarker
approach should be valuable not only for prognostic and diagnostic
procedures, but also for understanding disease mechanisms.
Following this reasoning, analysis of biomarker panels is highly
desirable in clinical trials, and therefore, multiplexing capabilities
are becoming of key importance for biomarker veriﬁcation and
validation. In this sense, alternative multiplexed antibody-based
protein quantiﬁcation methods, such as protein arrays51 and
bead-based immunoassays52, offer improved potential although
they still require costly and lengthy antibody development.
Biomarker identiﬁcation and qualiﬁcation in clinical proteomics
need speciﬁc recommendations53,54; technical speciﬁcations
related to the procedure should be reported e.g., deviations of mass
and other parameters (retention time, migration on gel, etc.). It is
also necessary to report the observed deviation in identifying pa-
rameters and (relative) abundance when the same sample is
analyzed repeatedly.
In comparison with antibody-based strategies, LCeMS-based
procedures exhibit a supreme high speciﬁcity towards preciseepitopes, peptides or protein isoforms; it is well-suited for multi-
plexing, but with the drawbacks of limited sensitivity (especially in
complex matrices such as plasma or serum) and throughput.
Therefore, novel approaches combining immunoenrichment
(which reduces sample complexity and allows higher sensitivity)
followed by high-throughput, highly-selective, targeted MS anal-
ysis, appear to be promising strategies for routinely screening
multiple biomarkers in hundreds of samples as required for
biomarker veriﬁcation55. In our ﬁeld of OA biomarkers, this strategy
has been applied to great advantage in the measurement of the
aggrecan-ARGS protein neo-epitope using speciﬁc antibodies for
the afﬁnity puriﬁcation of protein fragments combined with
detection using mass spectrometry56.
Other methodological considerations
Some fundamental concerns can be raised during the develop-
ment of diagnostic tests, which command additional validation
steps to suitably assess the value of the bioanalytical method before
clinical application. These include the following:
(1) Bias from inappropriate subject selection. To discern
“discriminatory” characteristics (e.g., OA vs controls) in a
rigorous and reproducible fashion, it is imperative to collect
well-annotated biosamples prospectively or retrospectively,
and in compliance with a well-designed protocol that is
powered to obtain statistically important outcomes. Since
they can inﬂuence biomarker levels, data should be collected
on other skeletal alterations, other conditions, and concom-
itant medications.
(2) Inappropriate sample size. Clinical biomarker studies
routinely suffer from a lack of proper experimental design,
resulting in analysis of too few biospecimens to achieve
adequate statistical power at each stage of a biomarker
pipeline. In proteomics research, a consensus is being built to
set statistical criteria for clinical relevance and an approach
to calculate sample size57. Rigorous evaluation of sample size
and statistical power should be conducted prior to study
execution to ensure conclusive results and to minimize
misattribution of lack of effect due to low statistical power.
(3) Type and timing of samples. Biomarker levels may vary with
gender, age, menopausal status, ethnicity and OA risk factors
such as body mass index. Furthermore, serum and urinary
levels of most proposed OA markers, such as Cartilage Olig-
omeric Matrix Protein (COMP), the C-propeptide of collagen
type II (CPII) or the carboxy-terminal cross-linked telopep-
tide of type II collagen (CTX-II) can be modiﬁed by diurnal
change, food intake or physical activity, as previously
reviewed19. Regarding the choice of plasma or serum for
analysis it is important to highlight that, while both types of
samples have similar protein compositions at a global level,
the expression, stability or recovery of individual proteins
may vary greatly. While the HUman Proteome Organization
(HUPO) recommends EDTA-plasma for proteomics studies58,
biomarker data generated in OA clinical trials to date have
been most commonly reported in serum.
(4) Bias from sample collection, processing and storage. As
mentioned above, strict SOPs for sample harvest, manage-
ment and distribution must be implemented to control
preanalytical variability. Reliable biosample banks are
required to assess the ability of the markers to discriminate
among groups of subjects in an unbiased manner.
(5) Data over-ﬁtting. This refers to the tendency of models
trained on large numbers of variables measured on small
numbers of samples to produce extraordinarily high
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validation sets. This problem has been exacerbated by
“omics” technologies, which produce thousands of variables
for each sample or subject. To solve this concern, cross-
validation of the results across several multiparametric sta-
tistical models and independent validation sets are needed59.Statistical considerations
Details of statistical analysis procedures and reporting of re-
sults can be obtained in the article concerning statistical consid-
erations that accompanies this special issue. Generally, the level of
sophistication in planning or reporting biomarker studies has been
very low, and inconsistent. Rarely does reporting extend beyond a
simple association of an outcome with the concentration of a
biomarker whose source is ill deﬁned. Here we provide some basic
information that should be included in describing data analysis
and reporting of results of biomarker analyses, and discuss
some methodological issues pertinent to biomarker statistical
analyses.
 Proper analytic techniques to address non-independence of data
points
If study data are gathered across multiple data points, the
analysis plan should be consistent with methods used for sample
size and power analysis that is centered around primary outcomes.
Appropriate methods should be used accounting for data non-
independence (two knees of the same person), repeated mea-
sures over time. For example, regressions with variance adjust-
ments using generalized estimating equations (GEE) should be
considered if multiple joints of the same persons are considered in
the analysis. Alternatively, analysis could use data from only one
joint per person, selected either at random or by severity (e.g.,
worst joint, based on standardized assessment).
 Methods for imputing out of range values
The data should be checked for completeness to ensure
discrimination between missing data and out of range values. Out
of range values should be imputed in a standardized fashion that is
consistent across studies. For example, consensus should be
reached if the actual imputed values should be the lowest level of
detection, the mid-value between 0 and the lowest level of detec-
tion or some other method such as interpolation from the standard
curve extended below the lowest standard (method most appro-
priate for cases where the standard curve can be shown to be linear
in this range and presumably superior to random imputation of
these low values).
 Prognostic biomarkers can be used to enrich a trial for pro-
gressors or for predicting treatment response
There are two analytical approaches to this type of biomarker.
First, it is possible to use the entire distribution of responses to the
treatment and correlate with the baseline biomarker concentra-
tions. Alternatively, it is possible to compare biomarkers by groups
based on a responder criterion, such as the OMERACT-OARSI
responder criteria for OA clinical trials60, and evaluate the bio-
markers in those that respond compared to non-responders. The
type of analysis should correspond to the pre-deﬁned analysis plan
and be consistent with analysis performed for sample size esti-
mation. A variety of responder deﬁnitions can be identiﬁed along
the cumulative distribution of the response curve. Standardization of biomarkers
To ensure comparability across studies and across biomarkers it
is useful to utilize standardized scores that could express clinically
meaningful changes in units of standard deviation. Such an
approach could standardize reporting and aggregation of data
across studies.
Summary of recommendations and research agenda
As stated by Fleming et al.30, a prognostic factor does not an effect
modiﬁer make and a correlate does not a surrogate make. A long-
term advantage to biomarker development and use in the drug
development process is the advancement of tools that could
contribute to personalized medicine. Personalized medicine may
be deﬁned as “a medical model using molecular proﬁling tech-
nologies for tailoring the right therapeutic strategy for the right
person at the right time, and determin [ing] the predisposition to
disease at the population level and to deliver timely and stratiﬁed
prevention” (Deﬁnition from European Commission Health
Research Directorate31). These principles can be seen as forming
the foundation for the research agenda to advance biomarkers for
clinical trial applications. The suggestions put forward here should
be regarded as strong recommendations rather than requirements.
Only by including biomarkers in trials, both at the hypothesis
generating and veriﬁcation stages, will their full potential be real-
ized in the drug development process.
(1) We recommend collection of biospecimens in all OA clinical
trials because,
 As noted in the clinical trial guidelines of 19961 and prior
OARSI FDA white paper on biomarkers19, here we
encourage ongoing collection and analysis of samples from
clinical studies and trials. Evidence from randomized
controlled trials are needed to determine whether bio-
markers are useful in identifying those individuals most
likely to receive clinically important beneﬁts from an
intervention; this will establish a rich resource of bio-
specimens in which to qualify biomarkers as efﬁcacy of
intervention markers in different treatment contexts.
 We also encourage collection of biospecimens from case
control and longitudinal studies. Although diagnostic
markers are not of primary importance in the current
structure of OA clinical trials, we anticipate that they will
be increasingly important, as we evolve to treating earlier
disease, at the molecular derangement stage, prior to
structural abnormalities by MRI or radiograph. The Stan-
dards for the Reporting of Diagnostic Accuracy (STARD)61,
are generally accepted guidelines in diagnostic studies.(2) An extensive overview of biomarker results from trials is
needed to give reliable estimates of the net effects of the
intervention on the clinically meaningful endpoint and on
the biomarker.
(3) Collect data on concomitant medicationsdlittle is known of
their effects on biomarker clearance.
(4) Gain greater recognition of OA as a serious disease to
establish a basis for OA drug development pathways
permitting the use of surrogate endpoints.
(5) Reporting guidelines for OA biomarker publications need to
be established, and be openly available at e.g., OARSI web-
site. These guidelines should include both “generic” aspects
for any biomarker reporting (which may be adopted from
other biomarker areas), and “OA-speciﬁc” aspects. The cur-
rent state of OA biomarker literature is very heterogeneous
with regard to quality and details of reporting, making it
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analysis, in spite of hundreds of publications. Examples of
generic information are antibody and assay speciﬁcs, sam-
pling and sample storage speciﬁcs, subject demographics,
and more. Examples of OA-speciﬁc information are index
joint structure information by radiography or MRI or other,
information on other joints, joint symptoms (by what pa-
tient reported outcome), comorbidities, medication, and
more. Statistical analysis methodology should be carefully
described. Manuscripts not adhering to these guidelines will
be less likely to be accepted for publication. By analogy to
the CONSORT checklist for randomized clinical trial manu-
scripts, a checklist for authors should be developed to
specify where in the submitted manuscript the different
information is available, and this should accompany manu-
script submission to facilitate review. Ultimately, higher
quality and transparency of biomarker reporting will sup-
port a better understanding of the role of biomarkers in OA.
Developing reporting guidelines will require an effort
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